Burlington, MA – RedShift Bioanalytics (RedShiftBio) appoints new European Director for Sales and Support and East Coast Regional Sales Manager to help satisfy demand for its award-winning protein characterization system. Mike Williams joins the team to lead sales across Europe, and Jin Kim will support the U.S Eastern Region. The AQS3pro was introduced and completed a very successful beta program with major biotherapeutic development groups in 2018 and is now being embraced into the analytical toolkit of companies developing life-saving biotherapeutics. Demand continues to grow as users discover the benefits of the technology to See Change™ in the secondary structure of proteins.

Mike has nearly two decades of experience in protein characterization using various analytical technologies. His breadth of technical knowledge is perfect to educate on the benefits of Microfluidic Modulation Spectroscopy (MMS) versus less sensitive techniques like FTIR and CD-UV. Mike joins RedShiftBio following a career in instrumentation sales and applications at Malvern Instruments, Rigaku, GE Healthcare and Sigma-Aldrich and PhD in biophysical characterization of membrane proteins from Warwick University.

Jin joins the team following a career at Charles River Labs, Bluestream Labs and a non-profit organization within the Drug Development Division specializing in the Biotherapeutic area including vaccine and immuno-oncology.

Jin’s experience in biologic and biosimilar development from pre-clinical characterization through clinical testing and commercialization, makes her an invaluable resource to biophysical characterization scientists looking to expand their analytical toolkit.

The AQS3pro is designed for the development, formulation and manufacture of biotherapeutics. Enabling five key measurements—aggregation, quantitation, stability, similarity, structure—the AQS3pro ramps up the sensitivity, dynamic range and accuracy of IR spectroscopy over the concentration range of 0.1 to 200mg/mL. It features a powerful, integrated bioanalytics software that delivers automated, walk away operation.

“I am excited to join the Redshiftbio team to be instrumental in supporting our Biotherapeutics clients via MMS technology and to accelerate their research & drug development process for their continued success,” said Jin, while Mike said: “I am very excited to be joining the RedShiftBio team, the company energy and product is fantastic, and I very much look forward to bringing the AQS3pro to scientists across the EU.”

If you would like to find out more about the AQS3pro then visit https://redshiftbio.com/mms.